Rislenemdaz is an investigational compound primarily studied for its potential in treating acute suicidal ideation and behavior in patients with major depressive disorder. It acts as a selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, specifically targeting overactivity in glutamatergic pathways that may contribute to severe depressive symptoms. Due to its rapid onset of action, rislenemdaz has been explored as a short-term intervention in emergency psychiatric settings, aiming to reduce suicidal thoughts within hours of administration. Clinical trials have focused on its intravenous formulation, assessing efficacy, safety, and optimal dosing in high-risk populations. While still under investigation, it represents a promising avenue for addressing unmet needs in mental health care, particularly where current antidepressants are too slow-acting to prevent immediate self-harm risk.